148 followers
RT @reneroblesce: These findings indicated particular advantages of ALEMTUZUMAB compared to FINGOLIMOD in patients stopping NATALIZUMAB. W…
RT @reneroblesce: These findings indicated particular advantages of ALEMTUZUMAB compared to FINGOLIMOD in patients stopping NATALIZUMAB. W…
We heard similar data at ECTRIMS: #alemtuzumab is superior to #fingolimod after stopping natalizumab cessation." https://t.co/cTdZX63YiH #pubmed #feedly
These findings indicated particular advantages of ALEMTUZUMAB compared to FINGOLIMOD in patients stopping NATALIZUMAB. Washout time was 63 days (mean) for FTY vs. 91 days (mean) for ALEM https://t.co/YjQ2huFZIY https://t.co/X95k098Mry
Very useful paper to help sequencing of drugs. "Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation" https://t.co/j2vgy9UATb https://t.co/Mq5pc0p7pC